NCT05586516 - A Study to Assess an ATX Inhibitor (IOA-289) in Patients with Metastatic Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 10, 2022

Primary Completion Date

December 1, 2025

Study Completion Date

March 1, 2026

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG

IOA-289

IOA-289 will be administered orally twice daily (BID), starting from C0D1. Gemcitabine and nab-paclitaxel will be administrated by IV infusion, weekly for 3 weeks of a 4 week cycle starting at C1D1.

Trial Locations (3)

37126

UO Oncologia of Azienda Ospedaliera Universitaria Integrata di Verona, Verona

53100

Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Siena

G12 0YN

Beatson West of Scotland Cancer Center, Glasgow